Efficacy and safety of a low-dose nivolumab regimen (240 mg) as neoadjuvant immunochemotherapy in Chinese patients with resectable non-small cell lung cancer: a prospective single-arm, exploratory studyJuntao Zou, Ying Wu, Shaoyun Nie et al.|International Immunopharmacology|2026Cited by 0